Callan JMB Announces Alabama State Partnership: Yet Another Unverified Revenue Claim

What happened

Callan JMB announced a strategic partnership with Alabama State University to advance pharmaceutical manufacturing and supply chain resilience, with management claiming a potential $414 million five-year revenue opportunity. This is the latest in a series of press releases touting large revenue potentials without SEC-filed contract evidence, consistent with a pattern of promotional storytelling. The DeepValue report rates CJMB as a WAIT, citing deteriorating fundamentals: FY2024 revenue fell to $6.6M from $13.2M, net loss of $(2.3)M, and operating cash burn of $(3.9)M in the first nine months of 2025. The company's pivot to cold-chain and federal deployment relies on an equity line (ELOC) that prices at 95% of the lowest daily trading price, increasing dilution as cash burn persists. Without quantified capex, commissioned assets, or named customers in SEC filings, this partnership adds no verifiable evidence of a business turnaround.

Implication

The persistent reliance on press releases rather than SEC-disclosed contracts suggests the company is desperate to boost visibility as fundamentals deteriorate. The partnership does not change the thesis: CJMB remains a dilution-funded story with no margin of safety. Only when the next 10-Q shows quantified retrofit capex, named customers, or reduced ELOC dependence should investors re-evaluate.

Thesis delta

The partnership with Alabama State University is consistent with the existing narrative of pivoting to pharmaceutical manufacturing and does not represent a fundamental shift. The report's thesis remains unchanged: CJMB's stock prices in a successful pivot without evidence, and the next few months will determine whether the Texas retrofit and Attune partnership convert into real revenue. This announcement does not increase the probability of a near-term inflection.